Hepatology International

, Volume 8, Issue 3, pp 352–364

Comparison of first- and second-wave DAAs for HCV GT1: efficacy, safety, tolerability, and regimen complexity

Authors

  • Blaire E. Burman
    • Division of Gastroenterology & Hepatology, Department of MedicineUniversity of California
  • Paul Y. Kwo
    • Division of Gastroenterology & Hepatology, Department of MedicineIndiana University
    • Benaroya Research InstituteUniversity of Washington
Review Article

DOI: 10.1007/s12072-014-9552-6

Cite this article as:
Burman, B.E., Kwo, P.Y. & Kowdley, K.V. Hepatol Int (2014) 8: 352. doi:10.1007/s12072-014-9552-6

Keywords

Hepatitis CDirect-acting antivirals

Copyright information

© Asian Pacific Association for the Study of the Liver 2014